Article
Efficacy and safety of telaprevir, pegylated interferon α-2b and ribavirin triple therapy in Japanese patients infected with hepatitis C virus genotype 1b.
Internal medicine (Tokyo, Japan) - 1 Jan 2015
Kawaguchi Yasunori, Iwane Shinji, Kumagai Takanori, Yanagita Kimihiko, Yasutake Tsutomu, Ide Yasushi, Otsuka Taiga, Eguchi Yuichiro, Ozaki Iwata, Akiyama Takumi, Kawazoe Seiji, Mizuta Toshihiko
Abstract excerpt
Objective This study evaluated the efficacy and safety of triple therapy with telaprevir (TVR), pegylated interferon α-2b (PegIFN-α-2b) and ribavirin (RBV) in Japanese patients chronically infected with hepatitis C virus (HCV) genotype 1b in real-world clinical practice. Methods A total of 106 consecutive patients with HCV genotype 1b were treated with triple therapy for 12 weeks followed by dual therapy with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.